参芪降糖颗粒联合利拉鲁肽用于二甲双胍治疗失效的2型糖尿病患者的应用价值  

Application value of Shenqi Jiangtang granules combined with liraglutide in patients with type 2 diabetes who do not respond to metformin therapy

作　　者：蒙绪标[1] 刘婷婷[1] 符兰芳[1] 熊青[1] 林珠 MENG Xubiao;LIU Tingting;FU Lanfang;XIONG Qing;LIN Zhu(Department of Endocrinology,Haikou People′s Hospital,Haikou 570208,China)

机构地区：[1]海南省海口市人民医院内分泌科,海口570208

出　　处：《实用医学杂志》2021年第11期1489-1493,共5页The Journal of Practical Medicine

基　　金：海南省海口市重大科技创新项目(编号:2014-71)。

摘　　要：目的探究参芪降糖颗粒联合利拉鲁肽用于二甲双胍治疗失效的2型糖尿病患者的应用价值。方法将2017年4月至2019年10月于本院就医的150例2型糖尿病患者分为A、B、C三组,每组各50例。所有患者给予二甲双胍治疗,A组给予利拉鲁肽,B组给予参芪降糖颗粒,C组给予参芪降糖颗粒联合利拉鲁肽,对比三组治疗前后血糖水平、疗效、内脂素、胰岛功能、中医证候积分和不良反应。结果治疗后C组的血糖指标水平均明显低于A组和B组(P<0.05)。治疗后A组的总有效率为78%,B组的总有效率为82%,C组的总有效率为96%,C组总有效率显著高于A组和B组(P<0.05)。治疗后C组的内脂素水平均明显低于A组和B组(P<0.05)。治疗后C组的HOMA⁃β明显高于A组和B组(P<0.05)。治疗后C组的中医证候积分明显低于A组和B组(P<0.05)。三组在治疗过程中均未出现严重不良反应(P>0.05)。结论联合用药可显著提高疗效且未增加药物不良反应,可应用于二甲双胍治疗失效的2型糖尿病。Objective To explore the application value of Shenqi Jiangtang granules combined with lira⁃glutide for type 2 diabetic patients who do not respond to metformin therapy.Methods A total of 150 patients with type 2 diabetes who received treatment in our hospital from April 2017 to October 2019 were divided into three groups:A,B,and C,with 50 subjects in each group.All patients received metformin,group A was given liraglu⁃tide,group B was given Shenqi Jiangtang granules,and group C was given Shenqi Jiangtang granules combined with liraglutide.The blood glucose levels,efficacy,visfatin,pancreatic islet function,TCM syndrome scores and adverse reactions of the three groups were compared before and after the treatment.Results After treatment,the blood glucose level of group C was significantly lower than that of group A and group B(P<0.05).The total effec⁃tive rate of group A、B and C was 78%,82%and 96%,respectively.The total effective rate of group C was signifi⁃cantly higher than that of group A and group B(P<0.05).The level of visfatin in group C was significantly lower than that in group A and group B(P<0.05).The HOMA⁃βof group C was significantly higher than that of group A and group B(P<0.05).The TCM syndrome score of group C was significantly lower than that of group A and group B(P<0.05).No serious adverse reactions were found in the three groups(P>0.05).Conclusion Shenqi Jiangtang granules combined with liraglutide could significantly improve the efficacy without increasing adverse drug reactions,and could be applied to type 2 diabetes patients who do not respond to metformin.

关 键 词：2型糖尿病 利拉鲁肽 参芪降糖颗粒 内脂素 胰岛功能 

分 类 号：R587.1[医药卫生—内分泌]